SEC Form 8-K Summary
Registrant: Adagio Therapeutics, Inc. (now identified in the request metadata as Invivyd, Inc.; the provided filing itself names Adagio Therapeutics, Inc.)
Report date: March 30, 2022. The filing reports on the fourth quarter and year ended December 31, 2021.
Business Context and Filing Purpose
The company furnished a corporate update and announced financial results for the fourth quarter and full year 2021 under Item 2.02 of Form 8-K. The filing incorporates by reference a March 30, 2022 press release as Exhibit 99.1, but the press release text and detailed financial statements are not included in the provided source.
Financial Metrics
- Revenue, net loss or profit, operating expenses, cash flow, cash and cash equivalents, margins, debt, and liquidity figures are not provided in the filing text supplied.
- The filing states that 2021 fourth-quarter and full-year financial results were announced, but it does not provide the underlying amounts or comparable-period changes.
Material Changes, Outlook, and Risks
- The filing does not provide sufficient detail to summarize material changes versus the prior comparable periods.
- Guidance, forward-looking outlook, management commentary, contingencies, and unusual items are not included in the provided text.
- The company’s common stock traded on Nasdaq under the symbol ADGI at the filing date.
- The company identified itself as an emerging growth company.
Investor Verification Items
- Obtain and review Exhibit 99.1 for the actual fourth-quarter and full-year 2021 results, cash position, operating expenses, and management outlook.
- Verify the company’s corporate name and any subsequent name, ticker, or business changes, because the supplied metadata identifies Invivyd, Inc. while the filing identifies Adagio Therapeutics, Inc.
- Review the complete financial statements and related SEC filings for debt, liquidity runway, cash burn, revenue recognition, and risk disclosures.